COCP

COCP Stock Increases Over 15% Pre-Market: Why It Happened

Cocrystal Pharma Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A, Plans to initiate a Phase 1 Trial in the Third Quarter

Cocrystal Pharma's Preclinical Protease Inhibitor Effective Against Original, Two Variant COVID-19 Strains

COCP Stock Price: Over 10% Increase Pre-Market Explanation

Cocrystal's Lead COVID-19 Antiviral CDI-45205 Shown to be Active Against SARS-CoV-2 and Two Prominent SARS-CoV-2 Variants

Cocrystal Pharma's Participation in the Noble Capital Markets C-Suite Interview Series is Now Available Online

Target Highly Promising Antiviral Therapeutics with Cocrystal Pharma